Boehringer Ingelheim inaugurates the Shanghai "Center of Competence"

Boehringer IngelheimBoehringer Ingelheim celebrated the inauguration of its new "Center of Competence" (CoC) in Shanghai. As part of the company's EUR 100 million expansion project in China, the CoC entails an investment of EUR 10 million and will specialise in optimising active pharmaceutical ingredients (APIs) and chemical intermediates procured in China. So far, more than 20 highly-qualified organic and analytical chemists have been recruited for the CoC.

"This reinforces our company's determination and commitment to continue investing in China," said Prof. Wolfram Carius, Member of the Board of Managing Directors of Boehringer Ingelheim and responsible for the Board Division Human Resources and Operations. "We attach great importance to the exchange with our Chinese partners. We have a long-term commitment to this market and we are driving innovation in the country's pharmaceutical industry."

The new CoC consists of the two departments Process Development (PD) and Quality Control (QC). The main functions of PD are to focus on the production process optimisation and the corresponding technology transfer to the company's partners within China in order to increase the production efficiency and precision.

David Preston, Chief Executive Officer of Boehringer Ingelheim China, said: "The inauguration of CoC is a milestone for Boehringer Ingelheim's development in China. By optimising the production process of our partners and securing the quality of the intermediates, China will play a stronger role in the company's global procurement efforts."

In 2009, the company announced a EUR 100 million expansion plan in China to expand its production capacity in Shanghai Zhangjiang High-Tech Park and to set up the center of competence which is now being opened.

About Boehringer Ingelheim in China
The laboratories of CoC are currently located at Waigaoqiao Free Trade Zone, Pudong, Shanghai. It covers an area of about 2,000 square meters. The CoC has been tested since May 2010 and is scheduled to be officially in operation in September 2010.

Boehringer Ingelheim set up its China branch office in March 1994. A year later, Boehringer Ingelheim International Trade (Shanghai) Co., Ltd. was registered. In 1995, Boehringer Ingelheim Shanghai Pharmaceuticals Ltd. was established. In 2002, the company set up its production plant in Shanghai Zhangjiang High-tech Park. It has introduced a state-of-the-art manufacturing facility that strictly follows international GMP standards. Currently, the company has offices in Shanghai, Beijing, Guangzhou and Chengdu with around 2,000 employees.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees.Since it was founded in 1885, the family-owned company has been committed for 125 years to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. Boehringer Ingelheim is recognised for the excellence of its product pipeline covering therapeutic areas ranging from respiratory, cardiovascular to central nerve system medicines. In recent years, the company also successfully advanced its research in diseases including diabetes and tumors. In 2009, Boehringer Ingelheim posted net sales of EUR 12.7 billion while spending 21% of net sales in its largest business segment, Prescription Medicines, on research and development.

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...

Another mRNA-based vaccine candidate protects anim…

An experimental messenger RNA (mRNA)-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits protective immune responses in mice and no...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Pfizer and BioNTech announce an agreement with U.S…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of...

Pfizer and BioNTech announce agreement with the Un…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candid...

Pfizer and BioNTech choose lead mRNA vaccine candi…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a singl...